Tempus AI, Inc. (NASDAQ:TEM) is one of the
10 Best ARK Stocks to Buy Right Now.
On May 14, Tempus AI, Inc. (NASDAQ:TEM) announced a collaboration with Bristol Myers Squibb to maximize clinical trials. The partnership will use multimodal data and AI to improve trial design and boost the probability of technical and regulatory success across five programs. CEO of Data and Apps at Tempus AI, Inc. (NASDAQ:TEM), Ryan Fukushima, said that the Bristol collaboration helps “unprecedented precision” in stratifying patients.
On May 5, the company reported first-quarter revenue rising 36.1% year over year to $348.1 million. Diagnostics revenue went up by 34.7% to $261.1 million, and data and applications revenue climbed 40.5% to $87.0 million, the company said. MRD testing volume surged about 500% year over year, yet losses widened.
Dragon Images/Shutterstock.com
Net loss came in at $125.9 million, compared with $68.0 million a year earlier, while adjusted EBITDA narrowed to a $2.8 million loss, the company said. CEO Eric Lefkofsky said the quarter showed “accelerating demand” for its AI platform.
Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology business that engages in combining artificial intelligence and machine learning with healthcare. It focuses on establishing platforms for cancer, neuropsychiatry, cardiology, infectious illness, and radiology.
While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
